Objective: Fibroblast growth factor receptor 3 (FGFR3) is a member of the fibroblast growth factor receptor tyrosine kinase family. The prognosis and management stratification of oral squamous cell carcinoma (OSCC) are based on histology and other factors; however, immunohistochemical (IHC) markers that can detect OSCC that are more malignant and with a worse prognosis have not been adequately investigated. OSCC expresses activated FGFR3 signaling, which is not associated with prognosis. Currently, we explored the association between FGFR3 overexpression or the proliferation and histopathological hierarchy and stratum of risk.Methods: A total of 62 patients who had been diagnosed with OSCC at our department between January 2008 and December 2013 were included. The IHC expression of FGFR3 and Ki67 was analyzed in 45 (n = 37 tongue, 7 floor of mouth, 3 buccal mucosa) cases of OSCC. JMP14.2 was used for statistical analysis.Results: A combined analysis of FGFR3high/Ki67high positivity resulted in a reduced mean overall survival (OS) of 67.3 months when comparing with all other combinations. In the multivariate analysis (MVA), high clinical stage (p = 0.036) and FGFR3high/Ki67high (p = 0.031) were significant independent risk factors for OS.Conclusions: We identified FGFR3high/Ki67high OSCC as a subgroup that has a weak prognosis and OS. OSCC grading should probably be augmented by IHC staining, and tumors classified as having a worse prognosis require appropriate clinical surveillance.
机构:
Lanzhou Univ, Sch Basic Med Sci, Key Lab Preclin Study New Drugs Gansu Prov, Lanzhou, Gansu, Peoples R China
Lanzhou Univ, Sch Stomatol, Key Lab Dent Maxillofacial Reconstruct & Biol Inte, Lanzhou, Gansu, Peoples R ChinaLanzhou Univ, Sch Basic Med Sci, Key Lab Preclin Study New Drugs Gansu Prov, Lanzhou, Gansu, Peoples R China
Huang, Ke
Meng, Yucheng
论文数: 0引用数: 0
h-index: 0
机构:
Lanzhou Univ, Sch Stomatol, Key Lab Dent Maxillofacial Reconstruct & Biol Inte, Lanzhou, Gansu, Peoples R ChinaLanzhou Univ, Sch Basic Med Sci, Key Lab Preclin Study New Drugs Gansu Prov, Lanzhou, Gansu, Peoples R China
Meng, Yucheng
Lu, Jiyuan
论文数: 0引用数: 0
h-index: 0
机构:
Lanzhou Univ, Sch Stomatol, Key Lab Dent Maxillofacial Reconstruct & Biol Inte, Lanzhou, Gansu, Peoples R ChinaLanzhou Univ, Sch Basic Med Sci, Key Lab Preclin Study New Drugs Gansu Prov, Lanzhou, Gansu, Peoples R China
Lu, Jiyuan
Xu, Lingdan
论文数: 0引用数: 0
h-index: 0
机构:
Lanzhou Univ, Sch Stomatol, Key Lab Dent Maxillofacial Reconstruct & Biol Inte, Lanzhou, Gansu, Peoples R ChinaLanzhou Univ, Sch Basic Med Sci, Key Lab Preclin Study New Drugs Gansu Prov, Lanzhou, Gansu, Peoples R China
Xu, Lingdan
Wang, Shiqi
论文数: 0引用数: 0
h-index: 0
机构:
Lanzhou Univ, Sch Stomatol, Key Lab Dent Maxillofacial Reconstruct & Biol Inte, Lanzhou, Gansu, Peoples R ChinaLanzhou Univ, Sch Basic Med Sci, Key Lab Preclin Study New Drugs Gansu Prov, Lanzhou, Gansu, Peoples R China
Wang, Shiqi
Wang, Huihui
论文数: 0引用数: 0
h-index: 0
机构:
Lanzhou Univ, Sch Stomatol, Key Lab Dent Maxillofacial Reconstruct & Biol Inte, Lanzhou, Gansu, Peoples R ChinaLanzhou Univ, Sch Basic Med Sci, Key Lab Preclin Study New Drugs Gansu Prov, Lanzhou, Gansu, Peoples R China
Wang, Huihui
Xu, Zhaoqing
论文数: 0引用数: 0
h-index: 0
机构:
Lanzhou Univ, Sch Basic Med Sci, Key Lab Preclin Study New Drugs Gansu Prov, Lanzhou, Gansu, Peoples R ChinaLanzhou Univ, Sch Basic Med Sci, Key Lab Preclin Study New Drugs Gansu Prov, Lanzhou, Gansu, Peoples R China
机构:
Anhui Med Univ, Dept Oncol, Clin Coll Chest, Hefei 230022, Peoples R China
Anhui Chest Hosp, Hefei 230022, Peoples R ChinaAnhui Med Univ, Dept Oncol, Clin Coll Chest, Hefei 230022, Peoples R China
Wang, Diming
Ye, Wei
论文数: 0引用数: 0
h-index: 0
机构:
Anhui Chest Hosp, Dept Pathol, Hefei 230022, Peoples R ChinaAnhui Med Univ, Dept Oncol, Clin Coll Chest, Hefei 230022, Peoples R China
Ye, Wei
Shi, Qingming
论文数: 0引用数: 0
h-index: 0
机构:
Anhui Med Univ, Dept Oncol, Clin Coll Chest, Hefei 230022, Peoples R China
Anhui Chest Hosp, Hefei 230022, Peoples R ChinaAnhui Med Univ, Dept Oncol, Clin Coll Chest, Hefei 230022, Peoples R China
Shi, Qingming
CANCER MANAGEMENT AND RESEARCH,
2021,
13
: 6429
-
6436